pirenzepine has been researched along with Diabetic Retinopathy in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruibal Francisco, JL | 1 |
| Benítez del Castillo, JM | 1 |
| Seara Aguilar, G | 1 |
| Fernández Vila, PC | 1 |
| Fernández Méndez, M | 1 |
| Reverte Blanc, F | 1 |
| García Sánchez, J | 1 |
| Casado de Frías, E | 1 |
1 other study available for pirenzepine and Diabetic Retinopathy
| Article | Year |
|---|---|
[Vitreous fluorophotometry and nocturnal GH secretion in young insulin-dependent diabetics treated with oral pirenzepine].
Topics: Administration, Oral; Adolescent; Child; Circadian Rhythm; Diabetes Mellitus, Type 1; Diabetic Retin | 1993 |